title: The immune system in the pathogenesis of ovarian cancer.
abstract: Clinical outcomes in ovarian cancer are heterogeneous even when considering common features such as stage, response to therapy, and grade. This disparity in outcomes warrants further exploration into tumor and host characteristics. One compelling host characteristic is the immune response to ovarian cancer. While several studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease, recent genetic and protein analyses also suggest a role in disease incidence. Recent studies also show that anti-tumor immunity is often negated by immune suppressive cells present in the tumor microenvironment. These suppressive immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathologic network. Thus, future research into immunotherapy targeting ovarian cancer will likely become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression or by disrupting critical cytokine networks.
authors.affiliation: Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Bridget
authors.initials: B
authors.lastname: Charbonneau
authors.forename: Ellen L
authors.initials: EL
authors.lastname: Goode
authors.forename: Kimberly R
authors.initials: KR
authors.lastname: Kalli
authors.forename: Keith L
authors.initials: KL
authors.lastname: Knutson
authors.forename: Melissa S
authors.initials: MS
authors.lastname: Derycke
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D002450:Cell Communication; D016207:Cytokines / Q000276:immunology; D005260:Female; D006801:Humans; D007107:Immune System; D010051:Ovarian Neoplasms / Q000276:immunology*; D019139:Tumor Escape; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D016207:Cytokines